



## How can you achieve MAX impact?

Elevate the standard of testing by addressing the three most prevalent non-viral sexually transmitted infections (STIs) in one assay.


- ▶ Simultaneously test for *Chlamydia trachomatis* (CT), *Neisseria gonorrhoeae* (GC) and *Trichomonas vaginalis* (TV)
- ▶ BD CTGCTV2 for BD MAX™ System tests for the most prevalent non-viral STIs at 1 time from 1 patient sample

## Introducing BD CTGCTV2 for BD MAX™ System

Visit [advancing-diagnostics.eu](http://advancing-diagnostics.eu) to find out how.









## Increasing numbers of curable STIs continue to jeopardize the health of adults and children around the world<sup>1,5</sup>

Global STI surveillance data from 2016 released by the World Health Organization (WHO) estimated 376 million new cases of four common non-viral STIs: CT, GC, TV, and syphilis<sup>5</sup>



- Of the four most prevalent non-viral STIs, **Trichomonas vaginalis** has the highest prevalence, with an estimated **156 million** infections per year.<sup>3</sup>
- Untreated CT, GC and TV infections are associated with an increased risk for HIV acquisition and transmission and preterm birth.<sup>8-10</sup>

Rate of reported confirmed gonorrhoea cases per 100,000 population, EU/EEA, 2018<sup>6</sup>



- From 2012 to 2018, notifications of GC in Europe increased by **93%**.<sup>7</sup>
- In women, untreated CT and GC infections can result in adverse health outcomes such as pelvic inflammatory disease, ectopic pregnancy, infertility, and other pregnancy complications.<sup>9,10</sup> In men, untreated CT and GC infections can result in testicular swelling and sterility.<sup>9,10</sup>

CT and GC are the two most commonly reported bacterial STIs in Europe.<sup>1</sup> Although TV remains a non-notifiable disease, it is the most prevalent STI in the world and likely causes more STIs than CT and GC combined in many populations.<sup>1,2</sup>

Screening populations at risk of infection with CT, GC, and TV contributes to overall disease reduction and reduces adverse health outcomes of STIs.<sup>1,3</sup> To encourage routine screening, it is **critical for labs and healthcare systems to offer STI tests that have a quick time to result and user-friendly techniques for processing.**<sup>4</sup>

## The right treatment starts with the right test.

### BD CTGCTV2 for BD MAX™ System offers:

- **Performance:** 2 GC gene targets are required for a positive GC result<sup>4</sup>
- **Efficiency:** Triplex Assay - 1 collection, 1 specimen and 1 run with automated sample preparation and result interpretation<sup>11</sup>
- **Flexibility:** A wide variety of convenient sample types can be utilised with this assay (see table for details).<sup>11</sup>

The **BD Molecular Swab Collection Kit** allows for a single vaginal collection swab to be utilised for both BD CTGCTV2 for BD MAX™ System and BD MAX™ Vaginal Panel.<sup>11,12</sup>



# MAXimise your investment in PCR

Collection Kit	BD Molecular Swab Collection Kit <sup>13</sup>			BD Molecular Urine Collection Kit <sup>14</sup>		PreservCyt <sup>®</sup> Liquid Based Cytology (LBC) Media <sup>15</sup>
	Vaginal swab (c)	Vaginal swab (p)	Endocervical swab (c)	Male urine (p)	Female urine (p)	Gynecological (c)
BD CTGCTV2 <sup>11</sup> for BD MAX <sup>™</sup> System <ul style="list-style-type: none"> <li>• <i>Chlamydia trachomatis</i></li> <li>• <i>Neisseria gonorrhoea</i><sup>*</sup></li> <li>• <i>Trichomonas vaginalis</i></li> </ul>	✓	✓	✓	✓	✓	✓
BD CTGC2 <sup>16</sup> for BD MAX <sup>™</sup> System <ul style="list-style-type: none"> <li>• <i>Chlamydia trachomatis</i></li> <li>• <i>Neisseria gonorrhoea</i><sup>*</sup></li> </ul>	✓	✓	✓	✓	✓	✓
BD MAX <sup>™</sup> Vaginal Panel <sup>12</sup> <ul style="list-style-type: none"> <li>• Bacterial vaginosis</li> <li>• <i>Candida</i> group</li> <li>• <i>C. krusei</i></li> <li>• <i>C. glabrata</i></li> <li>• <i>Trichomonas vaginalis</i></li> </ul>	✓	✓				

c = clinician-collected; p = patient-collected in a health-care setting

\* 2 GC gene targets are required for a positive GC result<sup>4</sup>

## Visit [advancing-diagnostics.eu](https://advancing-diagnostics.eu) to learn more about the BD Womens Health and STI solutions.

### References:


1. European Centre for Disease Prevention and Control (ECDC). *Developing a national strategy for the prevention and control of sexually transmitted infections*. Accessed on April 8, 2021, at <https://www.ecdc.europa.eu/en/publications-data/developing-national-strategy-prevention-and-control-sexually-transmitted>
2. Van Der Pol B, Williams J, Fuller D, et al. Combined Testing for Chlamydia, Gonorrhoea, and Trichomonas by Use of the BD Max CT/GC/TV Assay with Genitourinary Specimen Types. *Journal of Clinical Microbiology*. 2017;55(1):155–164. <https://doi.org/10.1128/JCM.01766-16>.
3. Centers for Disease Control and Prevention (CDC). *Sexually Transmitted Infections: National Strategic Plan for the United States, 2021-2025*. Accessed on April 13, 2020, at <https://www.hhs.gov/sites/default/files/STI-National-Strategic-Plan-2021-2025.pdf>
4. Van Der Pol B, Torres-Chavolla E, Kodsí S, et al. Clinical Performance of the BD CTGCTV2 Assay for the BD MAX System for Detection of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Trichomonas vaginalis* Infections. *Sexually Transmitted Diseases*. 2021;48(2):134-140. doi: 10.1097/OLQ.0000000000001280.
5. World Health Organization (WHO). *Report on global sexually transmitted infection surveillance 2018*. Accessed on April 8, 2021, at <https://www.who.int/reproductivehealth/publications/stis-surveillance-2018/en/>
6. European Centre for Disease Prevention and Control (ECDC). *Gonorrhoea: Annual Epidemiological Report for 2018*. Accessed on April 8, 2021, at <https://www.ecdc.europa.eu/sites/default/files/documents/gonorrhoea-annual-epidemiological-report-2018.pdf>
7. European Centre for Disease Prevention and Control (ECDC). *Infographic: Sexually transmitted infections: a long-standing and ongoing threat for public health*. Accessed on April 28, 2021, at <https://www.ecdc.europa.eu/en/publications-data/infographic-sexually-transmitted-infections-long-standing-and-ongoing-threat>
8. Centers for Disease Control and Prevention (CDC). *Trichomoniasis: CDC fact sheet*. Accessed on August 10, 2020, at [www.cdc.gov/std/trichomonas/trichomoniasis-factsheet.pdf](http://www.cdc.gov/std/trichomonas/trichomoniasis-factsheet.pdf).
9. Centers for Disease Control and Prevention (CDC). *Chlamydia: CDC fact sheet*. Accessed on August 10, 2020, at <https://www.cdc.gov/std/chlamydia/Chlamydia-FS.pdf>.
10. Centers for Disease Control and Prevention (CDC). *Gonorrhoea: CDC fact sheet*. Accessed on August 10, 2020, at <https://www.cdc.gov/std/gonorrhoea/Gonorrhoea-FS.pdf>.
11. BD CTGCTV2 for BD MAX<sup>™</sup> System [product insert]. Franklin Lakes, NJ: Becton, Dickinson, and Company; 2021.
12. BD MAX<sup>™</sup> Vaginal Panel [product insert]. Franklin Lakes, NJ: Becton, Dickinson, and Company; 2021.
13. BD Molecular Swab Collection Kit [product insert]. Franklin Lakes, NJ: Becton, Dickinson, and Company; 2021.
14. BD Molecular Urine Transport Kit [product insert]. Franklin Lakes, NJ: Becton, Dickinson, and Company; 2020.
15. BD Molecular LBC Sample Buffer Tubes [product insert]. Franklin Lakes, NJ: Becton, Dickinson, and Company; 2020.
16. BD CTGC2 for BD MAX<sup>™</sup> System [product insert]. Franklin Lakes, NJ: Becton, Dickinson, and Company; 2021.

The BD MAX<sup>™</sup> System, BD MAX<sup>™</sup> Vaginal Panel, BD Molecular Swab Collection Kit, BD Molecular Urine Collection Kit and BD Molecular LBC Sample Buffer Tubes are in vitro diagnostic medical devices bearing a CE-mark.

The BD CTGCTV2 & BD CTGC2 for BD MAX<sup>™</sup> System are an in vitro diagnostic medical devices bearing a CE mark and is CE certified by BSI Group The Netherlands B.V. (Notified Body Number = 2797)

Assays have defined compatibility and most assays can be put in the same rack. User-defined protocols cannot be in the same rack as IVD assays.

BD Switzerland Sàrl, Terre-Bonne Park - A4, Route de Crassier 17, 1262 Eysins, Switzerland



[bd.com](https://www.bd.com)

